Rhofade — CareFirst (Caremark)

Initial criteria

• Patient has a diagnosis of rosacea.

Reauthorization criteria

• Patient has a diagnosis of rosacea.
• Patient has experienced a reduction in symptoms of rosacea from baseline (e.g., inflammatory papules or pustules, facial erythema).

Approval duration

Initial: 4 months; Continuation: Emrosi 12 months; Finacea, Mirvaso, Noritate, Rhofade, Soolantra 36 months